Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. As a leader in rare diseases for nearly 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries. Learn more at Alexion.com
Leiters is an FDA-registered 503B outsourcing provider of compounded sterile preparations that is committed to providing healthcare professionals and their patients with critically needed medications. Our team of experts in sterile pharmaceutical manufacturing, repackaging and compounding provide a sophisticated understanding of what it takes to elevate quality and consistency of supply in pharmaceutical outsourcing. We combine a deeply experienced team, with robust processes, in a state-of-the-art facility, to ensure delivery of the highest quality medicines. To learn more about how Leiters is Compounding Health™ please visit www.leiters.com
QuVa Pharma is a leading national 503B outsourcing services company providing sterile, ready-to-administer injectable medicines critical for high-quality patient care. QuVa was purpose-built to change the 503B industry for the better through unmatched expertise in cGMPs and sterile pharmaceutical manufacturing and achieves the highest quality and safety standards. Through our range of products and services, hospitals achieve resiliency and reliability to meet patient care and operational needs. Learn more at QuVaPharma.com.
Ritedose 503B Outsourcing Facility delivers on-demand, pre-filled syringe products for in-hospital care. Backed by Ritedose’s annual capacity of 2+ billion units and a 25-year, industry-leading track record that includes delivery of more than 8 billion uninterrupted doses since 2012, we use cGMP manufacturing and advanced blow-fill-seal (BFS) technology to ensure sterile, efficient and safe unit dose delivery. Our state-of-the-art facility exceeds FDA standards, meeting the most stringent cGMP and USP 797 guidelines. Learn more by clicking here.
RISCS is a rating and certification organization that evaluates the resilience of pharmaceutical supply chains. Our mission is to prevent drug shortages by helping drug purchasers identify manufacturers with robust supply chains. In collaboration with our advisory panel that includes the top 3 hospital GPOs in the US, leading pharmaceutical manufacturers, and other industry experts, we have launched the RISC Rating System™, a supply chain evaluation tool that translates non-public supply chain insights to drug purchasers. Learn more at RISCRatings.com
MMCAP Infuse is a national cooperative group purchasing organization serving government facilities across the nation that provide healthcare services. Membership is free and open to states and their agencies, as well as counties, cities, school districts, universities, and others. Members receive access to a full range of pharmaceuticals and healthcare products and services, including medical supplies, vaccines, dental supplies, drug testing, and nutritionals. Operated by the State of Minnesota’s Office of State Procurement, MMCAP Infuse has more than 18,000 members across all 50 states. Learn more here.